Adenosine has been shown to protect the ischemic and reperfused myocardium. To examine whether the protective effect of the nucleoside is mediated by modulation of oxidative stress, isolated rat hearts were perfused for 30 minutes with 100 ,uM H202 or an exogenous free radical-generating system consisting of purine (3.06 mM) and xanthine oxidase (10 units/l) in the presence or absence of drugs acting on adenosine A, or A2 receptors. H202 alone produced a greater than 90% loss in contractility concomitant with a threefold elevation in resting tension, although these effects occurred in the absence of ultrastructural damage. Two A, receptor agonists N6-cyclopentyladenosine (CPA, 1 gtM) and R(-)-N6-
been suggested that A, receptor activation accounts for the phenomenon of myocardial preconditioning that bestows cardioprotection against reperfusion injury after brief periods of ischemia.Y Although the beneficial effects of A, activation have been well documented, the mechanisms underlying this phenomenon are not completely understood. The generation of reactive oxygenderived species has been established as a major mechanism of cardiac dysfunction produced by reperfusion, particularly with regard to mediation of myocardial stunning.'3 Although the toxic effects of these compounds are minimized by endogenous scavenging systems, these protective mechanisms can be overwhelmed under conditions when the generation of free radicals and other reactive species, including hydrogen peroxide (H202), is elevated, as may occur after reperfusion of the ischemic myocardium. In view of the importance of these reactive species to the reperfused myocardium, we hypothesized that a potential explanation for the therapeutic effects of A, receptor activation could be related to attenuation of oxidative stress. In this regard, we used pharmacological approaches to assess the influence of A, receptor activation on injury produced by 1) an exogenous free radical-generating system consisting of purine plus xanthine oxidase as well as 2) the adminis-tration of H202, both of which have been demonstrated to produce myocardial injury.1415 Our study suggests a selective cardioprotective influence of A, receptor activation against H202-induced cardiac injury.
Materials and Methods Animals
Male Sprague-Dawley rats weighing between 275 and 325 g were purchased from Charles-River Canada Ltd., St. Constant, Canada. Animals were provided free access to food and water and were housed in the animal care facilities of the faculty of medicine, University of Western Ontario, in accordance with guidelines of the Canadian Council on Animal Care, Ottawa.
Heart Perfusion
Rats were killed by decapitation, and hearts were rapidly excised and placed in ice-cold Krebs-Henseleit buffer to produce an immediate cessation of contraction. Hearts were squeezed a few times to dislodge any clotted blood in the coronary vasculature and immediately mounted by the aorta for perfusion through the coronary arteries by use of the Langendorff technique, as described in detail previously. 16 The perfusion fluid was Krebs-Henseleit buffer consisting of (mM) NaCl 120, NaHCO3 20, MgCl2 1.2, KCl 4.63, KH2P04 1.17, CaCl2 1.25, and glucose 8. Some experiments were performed in which the CaCl2 concentration was reduced to 0.62 mM. The buffer was continuously gassed with a 95% 02-5% CO2 mixture; pH was 7.4. To ensure thermoregulation (37°C), the entire system was enclosed in a series of water-jacketed chambers and coils. Flow rate was maintained at 10 ml/min. Contractile function was assessed as apicobasal displacement via a force-displacement transducer (model FT03, Grass Instrument Co., Quincy, Mass.) attached to the ventricular apex and positioned to yield an initial preload resting tension of 2 g.16 This signal was further connected to a Grass 7P20 differentiator to obtain rates of force development (+dF/dt) and relaxation (-dF/ dt).'6 A side arm off the perfusion cannula was attached to a pressure transducer (model P23XL, Spectramed) for the recording of coronary pressure. Hearts were initially allowed to contract spontaneously; however, because of the negative chronotropic effect of numerous pharmacological interventions (see below), all hearts were subsequently stimulated at 3 times threshold at a rate of 5 Hz with a Grass S44 stimulator via platinum-needle electrodes inserted into the ventricular epicardium. Treatment Protocols All hearts were initially equilibrated for 15 minutes.
To study the effect of A,-selective agonists, N6-cyclopentyladenosine (CPA, 1 ,uM) or either of the diastereoisomers R(-)or S(+)-N6-(2-phenylisopropyl)adenosine (R-PIA or S-PIA, respectively, 1 ,uM) was added for 15 minutes before the addition of purine (3.06 mM) plus xanthine oxidase (13.33 units/l) or H202 (100 ,uM).
Hearts were then perfused for a further 30 minutes with the appropriate drug combination. We also examined the direct influence of the A, receptor antagonist 1,3dipropyl-8-cyclopentylxanthine (DPCPX, 0.5 ,uM) and the A2-selective agonist 2-[p-(carboxyethyl)phenethyl-1 ,uM) by using a similar approach. To examine the potential reversibility of A,-mediated effects, experiments were done in which DPCPX was administered 5 minutes before the addition of either CPA or PIA. Some experiments were done in which DL-propranolol (10 ,uM) was added 15 minutes before H202 administration by a protocol similar to that used for other agents. Adenosine receptor agonists and antagonists were purchased from Research Biochemicals Inc., Natick, Mass.; DL-propranolol was from Sigma Chemical Co., St. Louis, Mo. All of these drugs except S-PIA and DL-propranolol, which are soluble in water, were dissolved in absolute ethanol. The ethanol concentration in the perfusion buffer was 0.01%, which by itself was completely without effect on any parameter examined. Purine and xanthine oxidase were purchased from Sigma, and H202 was obtained from BDH Inc., Toronto,
Canada.
As noted above, CPA and PIA produced marked (>90%) negative chronotropic effects that were maximal after 5-10 minutes. Therefore, in all studies, the hearts were stimulated electrically as described above, 5 minutes before the addition of purine plus xanthine oxidase or H202 and for the remainder of the perfusion period.
Metabolite Assays
At the end of the perfusion period, hearts were rapidly clamped between tongs precooled in liquid nitrogen. Energy metabolites were measured spectrophotometrically in 6% perchloric acid extracts according to Bergmeyer17 and as described previously.'6 Energy charge was calculated from the following equation:
Electron Microscopy
Two hearts (treated with H202 only and H202 plus CPA) were immediately removed at the end of the perfusion period and perfusion-fixed at a constant perfusion pressure of 80 cm H20 with 150 ml fixative containing 0.08 M sodium cacodylate, 2% glutaraldehyde, and 1% paraformaldehyde, pH 7.4; after which, sections measuring approximately 1 cmxl mmxl mm were cut from the left ventricle. Subsequent processing and sectioning were performed at the Department of Pathology, University Hospital, London, Canada, using a Lynx automatic tissue processor. Tissues were postfixed with 1% osmium tetroxide and dehydrated with graded ethanol and acetone rinses. The final ethanol/ acetone solution was replaced by en bloc stain consisting of a 3:7 ratio of uranyl nitrate/saturated lead acetate solution for 1 hour. The tissues were infiltrated and embedded in Epon Araldite resin and polymerized overnight at 70°C. Thin sections (60-90 nm) were cut with a diamond microtome knife and stained with uranyl acetate and lead citrate. Samples were viewed on an electron microscope (model 109, Carl Zeiss, Inc., Thornwood, N.Y.).
Statistical Analysis
Data were analyzed using either a one-way or multifactorial analysis of variance for analysis of tissue metabolites or function, respectively Time (minutes) FIGURE 1. Graphs showing the response of isolated rat hearts to 100 ,iM H202 or the free radical-generating system consisting of 3.06 mM purine (P) plus 13.3 units/l xanthine oxidase (XO) in terms of developed force and resting tension. The results are mean +SEM offive experiments. Time refers to minutes after H202 addition. +When values were first significantly different (p<0.05) from those obtained before H202 or P+XO addition. mean±SEM. Differences were regarded as significant atp<0.05.
Results

Function Data
The profiles of contractile changes in terms of developed force or resting tension produced by either H202 or purine plus xanthine oxidase are shown in Figure 1 . This figure demonstrates the markedly greater degree of dysfunction in terms of contractile depression or resting tension elevation produced by H202. With either treatment, a significant depression in developed force was observed after 5 minutes of perfusion, whereas a significant effect (after 15 minutes) on resting tension was seen only with H202. Figure 2 shows the influence of 1 ,uM CPA on functional changes produced by H202. H202 alone produced a 90% loss in contractility concomitant with a threefold elevation in resting tension. The deleterious effect of H202 was significantly attenuated by CPA. In the presence of the A, agonist, the loss in function was markedly slowed, and the magnitude of depression in contractility was significantly diminished. Moreover, the elevation in resting tension was significantly attenuated by CPA to 170% (p<0.05 from H202 only and not significantly different from the pre-H202 value). Representative recordings showing the effects of H202 and the protective actions of CPA are given in Figure 3 . It is evident from this recording that H202 also decreased coronary pressure. None of the drugs studied modulated this effect, with the exception of CGS 21680 or 10 ,uM S-PIA, which alone reduced coronary pressure by 43±3% and 58±3%, respectively. After these pretreatments, H202 failed to produce further coronary relaxation (data not shown).
We also carried out a limited qualitative analysis to assess whether ultrastructural abnormalities occur as a consequence of H202 administration. As shown in Figure 4, no gross damage was observed in a heart perfused with H202 only (panels A and B) or, not unexpectedly, in one perfused with H202 plus CPA (panels C and D). Thus, the present model appears to be one in which contractile depression occurs in the absence of necrosis. To ensure that ischemia did not mediate any of the actions of H202, we also measured tissue lactate contents after various treatments. Lactate contents ranged from 2.8± 1.12 ,umol/g drywt (H202 alone) to 5.87+2.03 ,umol/g dry wt (H202 plus R-PIA), and no significant differences were found between any treatment group studied. Moreover, we found no relation between lactate content and contractile function, irrespective of treatment (data not shown). To further probe the role of the A, receptor, studies with CPA were repeated in the presence of the selective A1 receptor antagonist DPCPX (0.5 ,uM). DPCPX alone was without effect on contractile depression produced by H202; after 30 minutes of treatment, developed force, +dF/dt, and -dF/dt were decreased to 14+8%, 16+9%, and 14±6% of pre-11202 values, respectively, whereas resting tension increased by 246±27% (n=4, data not shown). However, DPCPX almost totally reversed the salutary effects of CPA to values not significantly different from those observed with H202 only. Thus, as shown in Figure 5 , in the presence of CPA plus DPCPX, contractility was reduced by approximately 90% of the pre-H202 values, a result not significantly different from that observed with H202 alone. Furthermore, resting tension increased by 250% after 30 minutes of treatment under these conditions ( Figure 5 ). Moreover, for all parameters, significant H202-induced effects occurred sooner in the presence of CPA plus DPCPX. Experiments were also conducted to examine the effects of R-PIA, as well as its substantially less potent diastereoisomer S-PIA, against H202-induced dysfunction. As shown in Figure 6 , 1 ,uM R-PIA significantly attenuated H202-induced contractile depression and prolonged the time required to produce significant depression, whereas an identical concentration of S-PIA was without effect. With regard to resting tension, a trend toward reduction in resting tension elevation was evident with R-PIA; however, this failed to reach statistical significance. Nonetheless, the time re-quired to produce a significant elevation in resting tension was increased to 25 minutes compared with 15 and 10 minutes observed with H202 alone or with H202 plus S-PIA, respectively. Surprisingly, in the presence of S-PIA, resting tension increased to values significantly greater than those seen with H202 alone after 20 minutes of treatment ( Figure 6 ). Although the data are not shown, the protective effect of R-PIA was reversed in the presence of 0.5 ,uM DPCPX to values not significantly different from those obtained with H202 alone (n=3). For example, after 30 minutes of H202 treatment in the presence of R-PIA and DPCPX, developed force, +dF/dt, and -dF/dt were decreased to 11+3%, 124%, and 9+3% of pre-H202values, respectively, and resting tension was elevated to 306±41%. In view of the lower potency of S-PIA at the A, receptor compared with R-PIA, experiments were performed using a 10-fold greater concentration of S-PIA (10 ,M) to determine if this compound could bestow similar protection against H202-induced dysfunction. As shown in Figure 7 , 10 ,M S-PIA produced a marked attenuation of H202-induced dysfunction. In the presence of this drug, the decline in contractility was reduced to 40%, and resting tension was elevated to 170% after 30 minutes of H202 treatment. These protective effects were totally abolished in the presence of DPCPX, and the time required to produce significant effects was decreased for all parameters (Figure 7) .
The effect of CGS 21680, an A2 receptor-selective agonist, was also examined. As shown in Table 1 , H202 produced identical reductions in contractility and elevations in resting tension irrespective of CGS 21680 administration.
As shown in Table 2 , neither hypocalcemic perfusion (0.62 mM CaCl2) nor treatment with propranolol mimicked the cardioprotective effects of A, receptor agonists.
A similar approach to that used for H202 was used to examine the effects of A1 receptor occupancy on cardiac dysfunction produced by the administration of purine plus xanthine oxidase. In contrast to its protective effects against 11202, CPA failed to influence either the magnitude or the time required to produce a depression in contractility or the elevation in resting tension produced by the free radical-generating system (Figure 8 ). Moreover, none of the other pharmacological manipulations had any effect against purine plus xanthine oxidase-induced dysfunction (data not shown).
Metabolite Data
Myocardial metabolic status after the various treatments is summarized in Table 3 . Thirty minutes of perfusion with H202 resulted in a significant reduction in high-energy phosphate and adenine nucleotide contents as well as in the energy charge compared with pre-H202 values. These effects were generally reversed by CPA, R-PIA, and the higher concentration of S-PIA to values not significantly different from those found before H202 administration and significantly greater than those seen in hearts perfused with H202 only. The most consistent effect was seen with CPA, particularly with regard to the reversal of the H202-induced reduction in energy charge. Addition of DPCPX before the A. receptor agonist partially reversed the metabolic status to values not significantly different from those produced by H202 alone. CGS 21680 was without effect on any parameter. Table 3 also shows the effects of purine plus xanthine oxidase on myocardial energy metabolism. Although a trend toward a reduction in high-energy phosphates and adenine nucleotides was evident, this was not significant, either in the presence or absence of CPA.
Discussion
Adenosine exerts numerous cardiac effects, including coronary vasodilation, which has led to the hypothesis that the nucleoside represents an important regulator of coronary vascular reactivity.1,2 Moreover, adenosine produces negative inotropic, chronotropic, and dromotropic effects and attenuates the myocardial response to catecholamines. 19 The effects of adenosine are mediated by specific membrane-bound receptors, specifically, A2 receptors in vasculature and A, receptors in cardiac myocytes, some of which are linked to stimulation or inhibition of adenylate cyclase, respectively. [8] [9] [10] [11] 20 Recent evidence has suggested that adenosine may also act as an endogenous cardioprotective agent, particularly in the ischemic and reperfused myocardium. For example, it has been shown in isolated rat hearts that adenosine and R-PIA delay the time to onset of ischemic contracture and enhance recovery on reperfusion. demonstrated a protective effect of adenosine infusion in terms of infarct size reduction after coronary artery occlusion and reperfusion. These authors have also demonstrated a protective effect of low doses of CPA and high doses of CGS 21680.7 Interestingly, adenosine has also been shown to protect the reperfused myocardium when administered at the time of reflow, thus precluding the necessity for pretreatment and potentially enhancing its clinical usefulness in reduction of postreperfusion myocardial dysfunction.22 Aside from the salutary effects of exogenous adenosine, it has also been reported that maintenance of extracellular adenosine concentration by prevention of adenosine catabolism with adenosine deaminase inhibitors or by the use of nucleoside transport inhibitors similarly produced salutary effects in the ischemic and reperfused rat and rabbit hearts.23"24 Although the beneficial effects of adenosine and its analogues against myocardial ischemia and reperfusion injury have been demonstrated, the mechanisms underlying these effects are uncertain. A proposed mechanism for the beneficial influence of adenosine is based on its reintroduction into the adenine nucleotide pool, thus resulting in improved de novo synthesis and ATP repletion on reflow.4 In this regard, an active myocardial adenosine transport system that mediates the rapid uptake and phosphorylation of exogenous adenosine has been demonstrated.25'26 Dependent on receptor specificity, adenosine can also produce various other effects, such as the inhibition of the release of, or the action of, norepinephrine,19'27 as well as attenuation of platelet or neutrophil activation.28'29 For obvious rea-sons, modulation of blood-borne factors can be excluded as a potential mechanism for the beneficial effects of adenosine or adenosine analogues under in vitro conditions, which suggests that these compounds are also able to protect the myocardium directly. In addition, attenuation of either platelet or neutrophil activation is mediated via A2 receptor activation, which would not explain the beneficial effects of selective A, receptor agonists.28'30 Such effects on A2 receptors offer the most likely explanation for the beneficial effect of high doses of CGS 21680 under in vivo conditions7 versus the lack of effect in the present report.
To overcome the potential problem of adenosine uptake and its subsequent metabolism to adenine nucleotides, we used relatively specific adenosine receptor modulators31 to probe the possible mechanisms of cardiac protection afforded by adenosine and its analogues.
To our knowledge, the present report demonstrates for the first time that adenosine A, receptor activation selectively inhibits the cardiotoxic effects of H202, a finding that could be of substantial importance in understanding the mechanisms of the cardioprotective actions of endogenous adenosine. In addition, the study suggests that A, receptor activation represents a useful approach in the development of strategies aimed at reducing postreperfusion dysfunction mediated by H202-induced oxidative stress, particularly since this selective approach would limit A2 receptor-mediated vasodilatation. The evidence for implicating A, receptor activation in the attenuation of H202-induced injury is based on a number of observations. First, cardioprotection was evident with three specific A, receptor agonists, and the degree of protection was consistent with the known rank order of potencies of these agonists at the A, receptor: CPA>R-PIA>S-PIA.32 Second, the salutary effects of all agonists were reversed by DPCPX, an A, receptor-selective antagonist that alone had no effect against H202-induced dysfunction. The inability of DPCPX to modulate H202-induced injury likely reflects the fact that in a well-oxygenated heart there is insufficient extracellular adenosine present to protect against H202. Last, it is important to point out that CGS 21680, an A2-selective agonist,3' failed to influence the effects of H202. However, it should be emphasized that in the present study we used a H202 concentration that produced contractile depression in the absence of gross cell damage. Whether A, receptor agonists possess similar protective actions vis-a-vis inhibition of cell and cell damage. 18 Indeed, one study reported a loss in ATP after cardiac arrest in the absence of change in the energy charge. 33 Nonetheless, our study does show a significant reduction in energy charge in hearts perfused with H202 alone or H202 plus CGS 21680, conditions that produced the greatest reduction in high-energy phosphate contents. In view of the fact that the drugs used in the present study are unlikely to be incorporated into the adenine nucleotide pool as is adenosine, the preservation of high-energy phosphate or total adenine nucleotide contents probably does not reflect an increased availability of the precursor. A possible explanation may lie in the fact that H202 has been shown to enhance intracellular calcium concentration, which may contribute to its cardiotoxic properties.34 Conversely, A, receptor activation is linked to depressed calcium influx either through the inhibition of cAMP-dependent phosphorylation of the calcium channel or enhanced potassium conductance,35 effects that could thus oppose the actions of H202 by attenuation of the intracellular calcium overload. Indeed, the reduction in resting tension elevation by A1 receptor agonists can also be attained, at least in the reperfused and reoxygenated heart, by calcium channel blockers,36 an observation that indirectly supports this contention. Surprisingly, however, our initial studies failed to demonstrate a protective effect of hypocalcemic perfusion against H202-induced toxicity. This may reflect the fact that 0.62 mM CaCl2, which was used in these experiments, was a concentration sufficiently high to mediate H202induced dysfunction. Nonetheless, this finding agrees with a recently completed study in our laboratory that showed that modulation of external calcium concentration or the use of calcium channel blockers failed to modify the cardiac response to exogenous H202 (K.M. Zimmer and M. Karmazyn, manuscript in preparation). Further studies are clearly required to more precisely probe the relation between calcium and H202-induced injury at the cellular level. We also attempted to determine the role of adrenergic mechanisms in H202induced toxicity by examining whether propranolol can mimic the salutary effects of A, receptor agonists. The inability of propranolol to modify the cardiac response to H202 suggests, but does not necessarily prove, that the salutary effects of A, receptor agonists are not related to an antiadrenergic mechanism.
A surprising observation was the specificity of Almediated effects for H202-mediated dysfunction despite 
